Home › Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma clinical trials recruiting in the U.S.
101 studies for Diffuse Large B-Cell Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY21 studies
- Baldwin Park, CA19 studies
- Chicago, IL18 studies
- Houston, TX17 studies
- Los Angeles, CA17 studies
- Milwaukee, WI16 studies
- Boston, MA16 studies
- Philadelphia, PA15 studies
- Portland, OR15 studies
- Durham, NC14 studies
- Nashville, TN14 studies
- Dallas, TX13 studies
- Seattle, WA12 studies
- Salt Lake City, UT12 studies
- Washington, DC12 studies
- Cincinnati, OH11 studies
- Denver, CO11 studies
- Cleveland, OH11 studies
- Rochester, MN10 studies
- Columbus, OH10 studies
- Richmond, VA10 studies
- Cedar Rapids, IA9 studies
- Edison, NJ9 studies
- Omaha, NE9 studies
- Atlanta, GA9 studies
- Jacksonville, FL8 studies
- Grand Rapids, MI8 studies
- New Haven, CT8 studies
- Greenburgh, NY8 studies
- San Antonio, TX8 studies
- Sacramento, CA8 studies
- St. Louis, MO8 studies
- Louisville, KY8 studies
- San Francisco, CA8 studies
- Miami, FL7 studies
- Aurora, CO7 studies
- Kansas City, MO7 studies
- Charlottesville, VA7 studies
- Indianapolis, IN7 studies
- Pittsburgh, PA6 studies
By state
- Alabama4 studies
- Arizona13 studies
- Arkansas4 studies
- California43 studies
- Colorado19 studies
- Connecticut8 studies
- District of Columbia4 studies
- Florida23 studies
- Georgia14 studies
- Idaho4 studies
- Illinois22 studies
- Indiana9 studies
- Iowa11 studies
- Kansas7 studies
- Kentucky11 studies
- Louisiana6 studies
- Maryland13 studies
- Massachusetts16 studies
- Michigan15 studies
- Minnesota16 studies
- Missouri8 studies
- Montana4 studies
- Nebraska9 studies
- Nevada3 studies
- New Jersey13 studies
- New Mexico3 studies
- New York31 studies
- North Carolina20 studies
- North Dakota4 studies
- Ohio24 studies
- Oklahoma5 studies
- Oregon16 studies
- Pennsylvania19 studies
- South Carolina4 studies
- South Dakota4 studies
- Tennessee18 studies
- Texas29 studies
- Utah14 studies
- Virginia17 studies
- Washington17 studies
- Wisconsin19 studies
Recently updated studies
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
RecruitingPhase 2
Ages 65 to 99 · All sexes · Updated Sep 29, 2026 · NCT05952024Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06977711Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06649812Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT03223610A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT03418038A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06890884A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05139017A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07519772A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06717347A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06091865Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06784167A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05757219Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT04002947A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06806033Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT05272384Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07225439Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT06500273Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT06784726Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07365306Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07284433From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.